Comparison of triple therapy, sequential therapy, and concomitant quadruple therapy of Helicobacter pylori

Comparison of triple therapy, sequential therapy, and concomitant quadruple therapy of Helicobacter pylori as a first-line therapy in Korea: a multicenter prospective randomized controlled trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CRIS

Registry ID

KCT0000703

Enrollment

510

Registered

2013-03-15

Start date

2013-04-02

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Eradication regimen for three gropus are as follows

1) standard triple therapy group: Pantoprazole 40 mg, amoxicillin 1.0 g, clarithromycin 500 mg bid for 10 days 2) sequential therapy group: Pantoprazole 40 mg, amoxicilliin 1.0 g bid for 5 days follow

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) male/female between 20 and 70 years old 2) agree to participate in this study 3) peptic ulcer disease, marginal zone B-cell lymphoma of stomach, early gastric cancer after endoscopic resection 4) H. pylori positive

Exclusion criteria

Exclusion criteria: 1) previous eradication therapy for H. pylori 2) severe systemic diseases such as hepatopathy, nephropathy, cardiopathy, and respiratopy diseases 3) in pregnant state and/or possibility of pregnancy during the study period 4) researcher's opinion

Design outcomes

Primary

Measure	Time frame
eradication rate	—

Secondary

Measure	Time frame
rates of adverse events	—

Countries

Korea, Republic of

Contacts

Public ContactKim Byung-Wook

The Catholic University of Korea, Incheon St. Mary's Hospital

bleok@naver.com+82-32-280-5052

Outcome results